ESSA Pharma Stock Price, News & Analysis (NASDAQ:EPIX) $5.05 -0.25 (-4.72%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$4.91▼$5.3650-Day Range$2.74▼$6.0052-Week Range$2.29▼$6.40Volume58,942 shsAverage Volume128,427 shsMarket Capitalization$222.71 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media ESSA Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside236.0% Upside$17.00 Price TargetShort InterestBearish6.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$454,274 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.69) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector709th out of 953 stocksPharmaceutical Preparations Industry309th out of 405 stocks 3.5 Analyst's Opinion Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, ESSA Pharma has a forecasted upside of 236.0% from its current price of $5.06.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.91% of the float of ESSA Pharma has been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in ESSA Pharma has recently increased by 1.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $454,274.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.00% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.69) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ESSA Pharma Stock (NASDAQ:EPIX)ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More EPIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPIX Stock News HeadlinesNovember 24, 2023 | msn.comESSA Pharma director Franklin Berger buys common shares worth ~$133.3KNovember 21, 2023 | finance.yahoo.comESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferenceDecember 6, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 8, 2023 | finance.yahoo.comESSA Pharma to Present at the Jefferies London Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comWe Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business GrowthOctober 30, 2023 | finance.yahoo.comEPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat…October 21, 2023 | finance.yahoo.comESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 CongressAugust 14, 2023 | finance.yahoo.comEPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23…December 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 14, 2023 | finance.yahoo.comESSA Pharma Inc. (NASDAQ:EPIX) is definitely on the radar of hedge funds investors who own 39% of the companyAugust 8, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023June 6, 2023 | finance.yahoo.comESSA Pharma Appoints Lauren Merendino to its Board of DirectorsJune 1, 2023 | finance.yahoo.comESSA Pharma to Present at 2023 Jefferies Healthcare ConferenceMay 24, 2023 | finance.yahoo.comWe're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash WiselyMay 18, 2023 | finance.yahoo.comEPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide…May 11, 2023 | finance.yahoo.comESSA Pharma to Present at JMP Securities Life Sciences ConferenceMay 9, 2023 | msn.comESSA Pharma: Q2 Earnings InsightsMay 9, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023April 18, 2023 | finance.yahoo.comESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2023 | ca.finance.yahoo.comESSA Pharma Inc. (EPIX)April 12, 2023 | finance.yahoo.comESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate CancerMarch 8, 2023 | finance.yahoo.comESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 7, 2023 | finance.yahoo.comESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measuresFebruary 23, 2023 | finance.yahoo.comEPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…February 7, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022February 2, 2023 | finance.yahoo.comESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology ConferenceJanuary 25, 2023 | finance.yahoo.comA Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)See More Headlines Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/18/2021Today12/06/2023Next Earnings (Estimated)12/12/2023Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+236.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17.25% Return on Assets-16.96% Debt Debt-to-Equity RatioN/A Current Ratio44.98 Quick Ratio44.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book1.34Miscellaneous Outstanding Shares44,100,000Free Float38,809,000Market Cap$223.15 million OptionableNot Optionable Beta1.97 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. David Ross Parkinson M.D. (Age 73)President, CEO & Director Comp: $798kMr. David S. Wood C.M.A. (Age 66)CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer Comp: $573.32kMr. Peter A. Virsik M.B.A. (Age 52)M.S., Executive VP & COO Comp: $625.36kDr. Alessandra Cesano M.D. (Age 62)Ph.D., Chief Medical Officer & Executive VP Comp: $598.03kChandtip ChandhasinExecutiveErica OsbourneExecutiveErin RudsinskiExecutiveLoleta HarrisExecutiveNeil ThaparExecutiveNkengyal BarberExecutiveMore ExecutivesKey CompetitorsGossamer BioNASDAQ:GOSSReneo PharmaceuticalsNASDAQ:RPHMOvid TherapeuticsNASDAQ:OVIDInozyme PharmaNASDAQ:INZYImmuneeringNASDAQ:IMRXView All CompetitorsInsiders & InstitutionsFranklin M BergerBought 23,259 shares on 11/21/2023Total: $133,274.07 ($5.73/share)Rock Springs Capital Management LPBought 13,688 shares on 11/15/2023Ownership: 1.535%Rhenman & Partners Asset Management ABSold 122,500 shares on 11/9/2023Ownership: 0.531%Group One Trading L.P.Sold 6,904 shares on 11/9/2023Ownership: 0.095%Franklin M BergerBought 60,000 shares on 11/2/2023Total: $321,000.00 ($5.35/share)View All Insider TransactionsView All Institutional Transactions EPIX Stock Analysis - Frequently Asked Questions Should I buy or sell ESSA Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares. View EPIX analyst ratings or view top-rated stocks. What is ESSA Pharma's stock price target for 2024? 1 equities research analysts have issued 12 month price targets for ESSA Pharma's shares. Their EPIX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 236.0% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts. How have EPIX shares performed in 2023? ESSA Pharma's stock was trading at $2.52 at the start of the year. Since then, EPIX shares have increased by 100.8% and is now trading at $5.06. View the best growth stocks for 2023 here. When is ESSA Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 12th 2023. View our EPIX earnings forecast. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) announced its earnings results on Thursday, November, 18th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX). Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (1.54%), Rhenman & Partners Asset Management AB (0.53%), Group One Trading L.P. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech. View institutional ownership trends. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EPIX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.